{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-013048","form_type":"8-K","ticker":"RNLXY","cik":"0001811115","company_name":"Renalytix plc","filed_at":"2024-02-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.629504+00:00","generated_at":"2026-06-06T04:56:42.934515+00:00","sec_items":["7.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"CMS publishes draft LCD for KidneyIntelX; coverage for type 2 diabetes and CKD stages 1-3b","bullets":["CMS draft LCD covers KidneyIntelX and kidneyintelX.dkd for patients with type 2 diabetes and Stage 1–3b chronic kidney disease.","Medicare price set at $950 per test; distinct CPT codes on 2024 Clinical Lab Fee Schedule.","45-day public comment period opened Feb 8, 2024; ends March 23, 2024; final LCD expected in 2024.","Company formally requested the LCD from NGS and submitted peer-reviewed evidence; expert panel meeting held Aug 29, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-013048","json":"https://secwatch.observer/filing/0000950170-24-013048.json","markdown":"https://secwatch.observer/filing/0000950170-24-013048.md","text":"https://secwatch.observer/filing/0000950170-24-013048.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1811115/000095017024013048/0000950170-24-013048-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1811115/000095017024013048/rnlx-20240209.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T04:56:42.934515+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}